Categories: HealthcareNews

Upcoming Publication on Social Media and Healthcare: Guide for Leadership and Strategies

NEW YORK, Sept. 12, 2024 /PRNewswire/ — BlueHuki, a premier digital marketing firm led by Dr. Heather Pressler, is proud to announce the acceptance of a chapter, titled “Social Media in Healthcare: Guide for Leadership and Strategies,” for publication in the forthcoming book, “New Horizons in Leadership: Inclusive Explorations in Health, Technology, and Education.”

The chapter was co-authored by Tiffany Zimmer and Joseph A. Greene, MD, MBA, FACS, FASMBS. Following a rigorous editorial review process, the chapter is slated for publication in the book by IGI Global within the next few months. This recognition underscores the authors’ expertise in social media strategies for leadership, particularly within the healthcare sector.

Dr. Pressler, the founder and CEO of BlueHuki, along with Tiffany Zimmer, have leveraged their extensive experience in social media platforms, content creation, and audience engagement to contribute valuable insights into a chapter on effective strategies for healthcare leadership.

The BlueHuki agency, established in 2022, has quickly become a notable player in the Washington, DC metro area, earning multiple accolades including being a finalist for Best of Falls Church in 2022, 2023, and 2024 in both New Business and Professional Services categories. Additionally, BlueHuki was awarded runner-up in 2023 and winner in 2024 for Best of D.C. Creative/Marketing Agency.

Joseph Greene, MD, MBA, FACS, FASMBS is a board-certified and fellowship-trained surgeon specializing in bariatric and general surgery at Capital Surgical Associates in Reston, Virginia, affiliated with Reston Hospital Center. He maintains a dedicated social media following and is known for his expertise in minimally-invasive and robotic techniques. He has been recognized as a Top Doctor by Washingtonian Magazine from 2021 to 2023.

Dr. Pressler remarked, “We hope that this chapter contributes to the discussion of best practices for healthcare leaders that are looking to use social media to promote accurate information, thoughtful discussion and improving equity in outcomes.”

The chapter enriches the publication with cutting-edge perspectives on integrating social media into healthcare practice and provides valuable guidance for healthcare leaders navigating the digital landscape. Dr. Greene’s contributions further underscore the chapter’s significance by bridging advanced surgical practice with innovative communication strategies. As a whole, the chapter exemplifies a commitment to advancing the respective fields and improving healthcare outcomes through effective leadership and strategic communication on social media.

View original content to download multimedia:https://www.prnewswire.com/news-releases/upcoming-publication-on-social-media-and-healthcare-guide-for-leadership-and-strategies-302247353.html

SOURCE BlueHuki Group LLC

Staff

Recent Posts

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate…

26 mins ago

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for…

27 mins ago

KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research…

27 mins ago

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one…

27 mins ago

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed…

27 mins ago